BetterLife PharmaCSE: BETR
BetterLife Pharma (CSE: BETR / OTC: BETRF) is a Canadian biotech developing BETR-001, a first-in-class non-hallucinogenic LSD derivative (2-bromo-LSD / BOL-148) for MDD, anxiety, and neuropathic pain. BETR-001 was acquired from Transcend Biodynamics LLC and activates the 5-HT2A receptor at 60% efficacy — sufficient for neuroplastogenic antidepressant effects but below the threshold for hallucinogenic effects. A composition of matter patent was granted January 2025, IND filing projected H1 2026.
Development Programmes
1BETR-001
MDD, anxiety, cluster headaches, TBI — non-hallucinogenic 5-HT2A partial agonist (2-bromo-LSD hemi-tartrate, (6R,9R) stereoisomer). Not the same as BOL-148.
Programme Tracker
Major Depressive Disorder (MDD)
IND-enabling studies near-complete. Pre-IND meeting with FDA completed. Favorable genotoxicity (Oct 2024) and cardiac safety (Nov 2024) data. USPTO composition of matter patent granted (Jan 2025). IND filing projected H2 2026. Non-controlled substance.
Milestones
Pre-clinical completed
CompletedActual: Oct 23, 2024
GLP genotoxicity study completed: no bone marrow toxicity, no mutagenic or clastogenic activity for oral BETR-001
Why it matters: Clean genotoxicity data is a critical IND-enabling milestone. BETR-001 is a 5-HT2A partial agonist (~60% activation vs LSD's ~90%) that produces neuroplastogenic effects without hallucinogenic activity. The genotox clearance removes a key regulatory risk.
Watch next: IND filing H2 2026
Pre-clinical completed
CompletedActual: Nov 25, 2024
Favorable cardiac safety data: minimal hERG channel impact — low cardiac arrhythmia risk
Why it matters: hERG safety is the second critical IND-enabling gate after genotoxicity. Minimal hERG impact means BETR-001 has a clean cardiovascular safety profile, differentiating it from compounds with QT prolongation liability.
Funding milestone
CompletedActual: Apr 3, 2024
Closed $1.168M convertible debentures to fund IND-enabling studies for BETR-001
Why it matters: BetterLife is a micro-cap (CSE:BETR, ~$9.4M market cap) funding development via convertible debentures rather than VC — a scrappy approach that preserves equity but limits speed. The $1.168M funds the critical IND-enabling tox studies.
Company milestone
CompletedActual: Jan 1, 2025
USPTO composition of matter patent granted for BETR-001
Why it matters: Patent protection secures exclusivity for the specific (6R,9R) 2-bromo-LSD hemi-tartrate stereoisomer. Non-controlled substance status plus patent protection creates a favorable regulatory and commercial landscape.
Recorded Events
Jan 1, 2025: Company milestone
Nov 25, 2024: Pre-clinical completed
Oct 23, 2024: Pre-clinical completed
Apr 3, 2024: Funding milestone
Quick Facts
- Type
- Public Biotech
- Ticker
- CSE: BETR
- Lead Stage
- Pre-clinical
- Website
- Visit